Y Yazdanpanah

Summary

Publications

  1. ncbi request reprint Prevention of human immunodeficiency virus-related opportunistic infections in France: a cost-effectiveness analysis
    Y Yazdanpanah
    Service Universitaire des Maladies Infectieuses et du Voyageur, Centre Hospitalier de Tourcoing, Faculte de Medecine de Lille, Lille, France
    Clin Infect Dis 36:86-96. 2003
  2. ncbi request reprint Clinical impact and cost-effectiveness of co-trimoxazole prophylaxis in patients with HIV/AIDS in Côte d'Ivoire: a trial-based analysis
    Yazdan Yazdanpanah
    Service Universitaire des Maladies Infectieuses et du Voyageur, Centre Hospitalier de Tourcoing, Faculte de Medecine de Lille, France
    AIDS 19:1299-308. 2005
  3. ncbi request reprint [Morbidity and cost of rotavirus infections in France]
    H Melliez
    Service universitaire régional de maladies infectieuses, Faculte de Medecine de Lille, 135, rue du Président Coty, BP 619, 59208 Tourcoing cedex, France
    Med Mal Infect 35:492-9. 2005
  4. ncbi request reprint [Risk factors for hepatitis C virus transmission to Health Care Workers after occupational exposure: a European case-control study]
    Y Yazdanpanah
    Service des Maladies Infectieuses et du Voyageur, Centre Hospitalier de Tourcoing
    Rev Epidemiol Sante Publique 54:1S23-1S31. 2006
  5. ncbi request reprint Efficacy and tolerance of rifampicin-linezolid compared with rifampicin-cotrimoxazole combinations in prolonged oral therapy for bone and joint infections
    S Nguyen
    Department of Infectious Diseases, Dron Hospital of Tourcoing, Tourcoing, France
    Clin Microbiol Infect 15:1163-9. 2009
  6. pmc Impact of Herpes simplex virus load and red blood cells in cerebrospinal fluid upon herpes simplex meningo-encephalitis outcome
    Julien Poissy
    Service universitaire de maladies infectieuses et du voyageur, Centre Hospitalier de Tourcoing, France
    BMC Infect Dis 12:356. 2012
  7. pmc Factors associated with presentation to care with advanced HIV disease in Brussels and Northern France: 1997-2007
    Bakhao Ndiaye
    CIRE Nord, Lille, France
    BMC Infect Dis 11:11. 2011
  8. pmc Drug efficacy by direct and adjusted indirect comparison to placebo: An illustration by Mycobacterium avium complex prophylaxis in HIV
    Jennifer Chu
    Division of General Medicine, Department of Medicine, Massachusetts General Hospital, Boston, USA
    AIDS Res Ther 8:14. 2011
  9. ncbi request reprint Risk factors for hepatitis C virus transmission to health care workers after occupational exposure: a European case-control study
    Y Yazdanpanah
    Service des Maladies Infectieuses et du Voyageur, Centre Hospitalier de Tourcoing, Faculte de Medecine de Lille, Tourcoing, France
    Clin Infect Dis 41:1423-30. 2005
  10. doi request reprint Multidrug resistance: a clinical approach
    Yazdan Yazdanpanah
    Service Universitaire des Maladies Infectieuses et du Voyageur, Centre Hospitalier de Tourcoing and EA 2694, Faculte de Medecine de Lille, Tourcoing, France
    Curr Opin HIV AIDS 4:499-506. 2009

Detail Information

Publications72

  1. ncbi request reprint Prevention of human immunodeficiency virus-related opportunistic infections in France: a cost-effectiveness analysis
    Y Yazdanpanah
    Service Universitaire des Maladies Infectieuses et du Voyageur, Centre Hospitalier de Tourcoing, Faculte de Medecine de Lille, Lille, France
    Clin Infect Dis 36:86-96. 2003
    ..Prophylaxis against fungal and cytomegalovirus infections is less cost-effective than are other therapeutic options for HIV disease and should remain of lower priority...
  2. ncbi request reprint Clinical impact and cost-effectiveness of co-trimoxazole prophylaxis in patients with HIV/AIDS in Côte d'Ivoire: a trial-based analysis
    Yazdan Yazdanpanah
    Service Universitaire des Maladies Infectieuses et du Voyageur, Centre Hospitalier de Tourcoing, Faculte de Medecine de Lille, France
    AIDS 19:1299-308. 2005
    ..In 2000, WHO/UNAIDS recommended co-trimoxazole prophylaxis for persons at early stages of HIV infection (WHO stage > or = 2) in sub-Saharan Africa...
  3. ncbi request reprint [Morbidity and cost of rotavirus infections in France]
    H Melliez
    Service universitaire régional de maladies infectieuses, Faculte de Medecine de Lille, 135, rue du Président Coty, BP 619, 59208 Tourcoing cedex, France
    Med Mal Infect 35:492-9. 2005
    ..Rotavirus is the most common cause of severe diarrhea in children. Morbidity and mortality related to rotavirus infection is not well known in temperate countries in general, and in France in particular...
  4. ncbi request reprint [Risk factors for hepatitis C virus transmission to Health Care Workers after occupational exposure: a European case-control study]
    Y Yazdanpanah
    Service des Maladies Infectieuses et du Voyageur, Centre Hospitalier de Tourcoing
    Rev Epidemiol Sante Publique 54:1S23-1S31. 2006
    ..The objective of this study was to assess potential risk factors for Hepatitis C seroconversion after occupational exposure to HCV...
  5. ncbi request reprint Efficacy and tolerance of rifampicin-linezolid compared with rifampicin-cotrimoxazole combinations in prolonged oral therapy for bone and joint infections
    S Nguyen
    Department of Infectious Diseases, Dron Hospital of Tourcoing, Tourcoing, France
    Clin Microbiol Infect 15:1163-9. 2009
    ..However, the lower cost of cotrimoxazole compared with linezolid renders RCC an attractive treatment alternative to RLC. Further larger clinical studies are warranted to confirm these preliminary results...
  6. pmc Impact of Herpes simplex virus load and red blood cells in cerebrospinal fluid upon herpes simplex meningo-encephalitis outcome
    Julien Poissy
    Service universitaire de maladies infectieuses et du voyageur, Centre Hospitalier de Tourcoing, France
    BMC Infect Dis 12:356. 2012
    ..Our aim was to determine the impact of Herpes simplex virus (HSV) load in cerebrospinal fluid (CSF) upon HSE outcome...
  7. pmc Factors associated with presentation to care with advanced HIV disease in Brussels and Northern France: 1997-2007
    Bakhao Ndiaye
    CIRE Nord, Lille, France
    BMC Infect Dis 11:11. 2011
    ....
  8. pmc Drug efficacy by direct and adjusted indirect comparison to placebo: An illustration by Mycobacterium avium complex prophylaxis in HIV
    Jennifer Chu
    Division of General Medicine, Department of Medicine, Massachusetts General Hospital, Boston, USA
    AIDS Res Ther 8:14. 2011
    ..abstract:..
  9. ncbi request reprint Risk factors for hepatitis C virus transmission to health care workers after occupational exposure: a European case-control study
    Y Yazdanpanah
    Service des Maladies Infectieuses et du Voyageur, Centre Hospitalier de Tourcoing, Faculte de Medecine de Lille, Tourcoing, France
    Clin Infect Dis 41:1423-30. 2005
    ..Additional studies are required to identify risk factors for hepatitis C virus (HCV) transmission to health care workers after occupational exposure to HCV...
  10. doi request reprint Multidrug resistance: a clinical approach
    Yazdan Yazdanpanah
    Service Universitaire des Maladies Infectieuses et du Voyageur, Centre Hospitalier de Tourcoing and EA 2694, Faculte de Medecine de Lille, Tourcoing, France
    Curr Opin HIV AIDS 4:499-506. 2009
    ..This review discusses the challenges that these new agents pose for the management of treatment-experienced patients...
  11. ncbi request reprint Incidence of primary opportunistic infections in two human immunodeficiency virus-infected French clinical cohorts
    Y Yazdanpanah
    Service Universitaire des Maladies Infectieuses et du Voyageur, Centre Hospitalier de Tourcoing, Centre Hospitalier Regional Universitaire de Lille, Tourcoing, France
    Int J Epidemiol 30:864-71. 2001
    ..The objective of this study was to estimate the incidence of primary opportunistic infections in HIV-infected individuals in geographically distinct cohorts in France...
  12. ncbi request reprint [Antiretroviral drugs in severe acute respiratory syndrome]
    Yazdan Yazdanpanah
    Service Universitaire des Maladies Infectieuses et du Voyageur, Centre Hospitalier de Tourcoing, Faculte de Medecine de Lille
    Presse Med 35:105-7. 2006
    ..The epidemiologic methods used to assess this drug's efficacy are not robust. Preliminary results for SARS treatment with protease and entry inhibitors, although at early stages of development, are promising...
  13. ncbi request reprint High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial
    Y Yazdanpanah
    Hôpital Tourcoing, Lille School of Medicine, Lille, France
    Clin Infect Dis 49:1441-9. 2009
    ..The aim of this study was to assess the safety and efficacy of a regimen containing raltegravir, etravirine, and darunavir/ritonavir for treatment-experienced patients infected with multidrug-resistant HIV...
  14. pmc CD4+ T-cell-guided structured treatment interruptions of antiretroviral therapy in HIV disease: projecting beyond clinical trials
    Yazdan Yazdanpanah
    Service Universitaire des Maladies Infectieuses et du Voyageur, Centre Hospitalier de Tourcoing, Tourcoing, France
    Antivir Ther 15:351-61. 2010
    ..We simulated continuous ART and STI strategies with higher CD4+ T-cell interruption/reintroduction thresholds than those assessed in actual trials...
  15. doi request reprint Earlier testing for HIV--how do we prevent late presentation?
    Yazdan Yazdanpanah
    Service Universitaire des Maladies Infectieuses et du Voyageur, Centre Hospitalier de Tourcoing, Tourcoing, France
    Antivir Ther 15:17-24. 2010
    ..They should also take advantage of rapid testing technologies and be aware of barriers to HIV testing among specific groups to provide opportunities for testing that are relevant to local communities...
  16. pmc Routine HIV screening in France: clinical impact and cost-effectiveness
    Yazdan Yazdanpanah
    Service Universitaire des Maladies Infectieuses et du Voyageur, Centre Hospitalier de Tourcoing, Tourcoing, France
    PLoS ONE 5:e13132. 2010
    ..Although previous studies have evaluated the cost-effectiveness of routine HIV screening in the United States, differences in both the epidemiology of infection and HIV testing behaviors warrant a setting-specific analysis for France...
  17. pmc The long-term benefits of genotypic resistance testing in patients with extensive prior antiretroviral therapy: a model-based approach
    Y Yazdanpanah
    Service Universitaire des Maladies Infectieuses et du Voyageur, Centre Hospitalier de Tourcoing, Tourcoing, France
    HIV Med 8:439-50. 2007
    ..Our objectives were to estimate the long-term effectiveness, cost and cost-effectiveness of genotype testing in patients with extensive antiretroviral exposure...
  18. ncbi request reprint Lifetime cost of HIV care in France during the era of highly active antiretroviral therapy
    Yazdan Yazdanpanah
    Service Universitaire des Maladies Infectieuses et du Voyageur, Centre Hospitalier de Tourcoing, Faculte de Medecine de Lille, France
    Antivir Ther 7:257-66. 2002
    ..To estimate the treatment and health care costs of HIV infection or AIDS in France during the era of highly active antiretroviral therapy (HAART)...
  19. pmc Clinical efficacy of antiretroviral combination therapy based on protease inhibitors or non-nucleoside analogue reverse transcriptase inhibitors: indirect comparison of controlled trials
    Yazdan Yazdanpanah
    Service Universitaire des Maladies Infectieuses et du Voyageur, Centre Hospitalier de Tourcoing, Faculte de Medecine de Lille, BP 619, F 59208 Tourcoing, France
    BMJ 328:249. 2004
    ..To compare the clinical efficacy of triple antiretroviral regimens based on protease inhibitors and non-nucleoside analogue reverse transcriptase inhibitors (NNRTIs) in adults positive for antibodies to HIV-1...
  20. ncbi request reprint Cost and cost-effectiveness of childhood vaccination against rotavirus in France
    H Melliez
    Service Universitaire des Maladies Infectieuses et du Voyageur, Centre Hospitalier de Tourcoing, France
    Vaccine 26:706-15. 2008
    ..To assess the effectiveness and cost-effectiveness of routine childhood vaccination by new vaccines against rotavirus in France...
  21. ncbi request reprint Cost-effectiveness of QuantiFERON-TB test vs. tuberculin skin test in the diagnosis of latent tuberculosis infection
    S Deuffic-Burban
    Institut National de la Santé et de la Recherche Médicale INSERM U795, Faculte de Medecine, Lille, France
    Int J Tuberc Lung Dis 14:471-81. 2010
    ....
  22. ncbi request reprint Incidence rate and risk factors for loss to follow-up in a French clinical cohort of HIV-infected patients from January 1985 to January 1998
    B Lebouche
    Department of Infectious Diseases, Tourcoing AIDS Reference Center, Dron Hospital, Tourcoing, France
    HIV Med 7:140-5. 2006
    ..To determine the incidence rate and risk factors for loss to follow-up (LFU) in HIV-infected individuals...
  23. ncbi request reprint ABCB1 allele polymorphism is associated with virological efficacy in naïve HIV-infected patients on HAART containing nonboosted PIs but not boosted PIs
    X De La Tribonniere
    Infectious Diseases Department, Tourcoing Hospital, Tourcoing, France
    HIV Clin Trials 9:192-201. 2008
    ..To assess the effect of the multidrug resistance-1 single nucleotide polymorphism (ABCB1 SNP) C3435T in exon 26 on the virological responses to first-line protease inhibitor (PI)-containing HAART regimens...
  24. ncbi request reprint Safety of prolonged high-dose levofloxacin therapy for bone infections
    E Senneville
    Infectious Disease Department, Dron Hospital, Tourcoing, France
    J Chemother 19:688-93. 2007
    ..001, respectively). A dosage of 750 mg q.d. may be warranted for prolonged high-dose levofloxacin treatment in patients with bone infections rather than 500 mg b.i.d. for the entire duration of treatment, or for the first 3 weeks...
  25. ncbi request reprint Incidence of and risk factors for severe liver toxicity in HIV-infected patients on anti-tuberculosis treatment
    E Pukenyte
    Department of Infectious Diseases, Centre Hospitalier de Tourcoing, Tourcoing, France
    Int J Tuberc Lung Dis 11:78-84. 2007
    ....
  26. ncbi request reprint Thymidine analogue mutations in antiretroviral-naive HIV-1 patients on triple therapy including either zidovudine or stavudine
    Laurence Bocket
    Service Universitaire de Virologie, Centre Hospitalier Regional de Lille, Lille, France
    J Antimicrob Chemother 53:89-94. 2004
    ....
  27. ncbi request reprint Expected response to protease inhibitors of HIV-1 non-B subtype viruses according to resistance algorithms
    Karen Champenois
    CRESGE LEM CNRS, Lille, France
    AIDS 22:1087-9. 2008
    ....
  28. doi request reprint Efficacy of new antiretroviral drugs in treatment-experienced HIV-infected patients: a systematic review and meta-analysis of recent randomized controlled trials
    M Pichenot
    Department of Infectious Diseases, Hospital of Tourcoing, Tourcoing, France
    HIV Med 13:148-55. 2012
    ..We compared CD4 cell count increases associated with chemokine (C-C motif) receptor 5 (CCR5) inhibitors or other new drugs, using indirect comparison...
  29. doi request reprint Characteristics and prognosis in patients with prosthetic vascular graft infection: a prospective observational cohort study
    L Legout
    Infectious Diseases Department, rue du Président Coty, 59208 Tourcoing, France
    Clin Microbiol Infect 18:352-8. 2012
    ..Overall in-hospital mortality was 16.5% (n=14). Two variables were independently associated with mortality: age >70 years (OR 9.1, 95% CI 1.83-45.43, p 0.007) and aortic graft infection (OR 5.6, 95% CI 1.1-28.7, p 0.037)...
  30. ncbi request reprint Effectiveness of childhood vaccination against rotavirus in sub-Saharan Africa: the case of Nigeria
    H Melliez
    Service Universitaire des Maladies Infectieuses et du Voyageur, Centre Hospitalier de Tourcoing, France
    Vaccine 25:298-305. 2007
    ..In this study in a sub-Saharan country, we showed that rotavirus vaccination with a new vaccine substantially reduces the number of deaths from rotavirus diarrhoea and may be of great use in developing countries...
  31. ncbi request reprint [Pneumonia in a traveller coming back from Asia]
    S Nguyen
    Service Universitaire des Maladies Infectieuses et du Voyageur, Centre Hospitalier de Tourcoing, 135, rue du Président Coty, 59208 Tourcoing, France
    Med Mal Infect 38:667-70. 2008
    ..Furthermore, choosing an empiric antibiotic treatment with fluoroquinolones could lead to treatment failure if the patient traveled in a country where fluoroquinolone resistance is high, as in Asia and especially in India...
  32. pmc Estimates of opportunistic infection incidence or death within specific CD4 strata in HIV-infected patients in Abidjan, Côte d'Ivoire: impact of alternative methods of CD4 count modelling
    Sylvie Deuffic-Burban
    CTRS, Unité INSERM 795, Hôpital Swynghedauw, CHRU de Lille, Lille, France
    Eur J Epidemiol 22:737-44. 2007
    ..All of the models indicate that the overall incidence of opportunistic infections under HAART in sub-Saharan Africa is high. This suggests that prophylaxis against opportunistic infections may be needed even for patients receiving HAART...
  33. ncbi request reprint Presence of HIV-1 Nef specific CD4 T cell response is associated with non-progression in HIV-1 infection
    Véronique Pancré
    UMR 8527 CNRS Lille II Institut Pasteur de Lille, Institut de Biologie, Lille, France
    Vaccine 25:5927-37. 2007
    ..So, early good T CD4 response to peptides of the Nef protein could thus be regarded as a factor of good prognosis in HIV infection and a tool of importance in the decision to put or not a patient under treatment...
  34. doi request reprint Mean cost of a first combination antiretroviral therapy in HIV-infected patients in France, and determinants of expensive drugs prescription
    V Colombié
    Service Universitaire des Maladies Infectieuses et du Voyageur, Centre Hospitalier Régional de Tourcoing, Faculté de Lille, Lille
    Int J STD AIDS 23:865-9. 2012
    ..81/day/person) to (33.12; P < 0.0001). Cost should be considered when choosing a first cART regimen, especially when considering clinically equivalent regimens...
  35. doi request reprint Skin and soft tissue infections due to Panton-Valentine leukocidin producing Staphylococcus aureus
    C Gros
    Infectious Diseases Department, Dron Hospital, Tourcoing, France
    Med Mal Infect 42:488-94. 2012
    ....
  36. doi request reprint Factors associated with delay to acyclovir administration in 184 patients with herpes simplex virus encephalitis
    J Poissy
    Service Universitaire des Maladies Infectieuses et du Voyageur, Tourcoing, France
    Clin Microbiol Infect 15:560-4. 2009
    ..8%), and three in six (3.3%). Patients with HSE often present with severe underlying disease, chronic alcohol abuse, or atypical CSF findings, and such factors should not be allowed to delay diagnosis and administration of acyclovir...
  37. ncbi request reprint Additional direct medical costs associated with nosocomial infections after head and neck cancer surgery: a hospital-perspective analysis
    N Penel
    Département de Cancérologie Générale, Centre Oscar Lambret, Lille, France
    Int J Oral Maxillofac Surg 37:135-9. 2008
    ..These results support the application of preventive interventions to reduce nosocomial infections in this setting...
  38. doi request reprint Staphylococcus simulans as an authentic pathogenic agent of osteoarticular infections
    M Mallet
    Infectious Diseases Department, Dron Hospital, Tourcoing, France
    Infection 39:473-6. 2011
    ..To evaluate the role of Staphylococcus simulans in bone and joint infections (BJI) and determine their main characteristics...
  39. ncbi request reprint Increased bleeding in HIV-positive haemophiliac patients treated with lopinavir-ritonavir
    Yazdan Yazdanpanah
    Service Universitaire des Maladies Infectieuses et du Voyageur, Centre Hospitalier de Tourcoing, Faculte de Medecine de Lille, France
    AIDS 17:2397-9. 2003
  40. ncbi request reprint Costs associated with combination antiretroviral therapy in HIV-infected patients
    Yazdan Yazdanpanah
    Service universitaire régional des maladies infectieuses et du voyageur, Centre Hospitalier de Tourcoing, Faculte de Medecine de Lille, 135, rue du Président Coty B P 619, F 59208 Tourcoing
    J Antimicrob Chemother 53:558-61. 2004
    ..More refined cost-effectiveness analyses are needed to evaluate available HIV/AIDS prevention, treatment, and care, and to identify the interventions that provide the best value for money...
  41. doi request reprint Opportunistic infections in patients with inflammatory bowel disease: prevention and diagnosis
    N Viget
    Service des Maladies Infectieuses et du Voyageur, Centre Hospitalier de Tourcoing, France
    Gut 57:549-58. 2008
    ..In the absence of national and international recommendations, the information given here should help doctors to optimise patient outcomes...
  42. ncbi request reprint [CCR5 antagonists: a new class of antiretrovirals]
    X De La Tribonniere
    Service des Maladies Infectieuses et du Voyageur, Centre Hospitalier Gustave Dron, Tourcoing, France
    Med Mal Infect 38:S1-6. 2008
    ....
  43. ncbi request reprint Treatment of bone and joint infections caused by Gram-negative bacilli with a cefepime-fluoroquinolone combination
    L Legout
    Division of Infectious Diseases, University of Lille, Dron Hospital, Tourcoing, France
    Clin Microbiol Infect 12:1030-3. 2006
    ..The results of the study confirmed the safety and effectiveness of cefepime combined with a fluoroquinolone for the treatment of bone and joint infections caused by Gram-negative bacilli...
  44. ncbi request reprint [Pneumonia with septicemia caused by Pasteurella multocida in an immunocompetent patient]
    E Pukenyte
    Service Universitaire des Maladies Infectieuses et du Voyageur, Centre Hospitalier de Tourcoing, 59208 Tourcoing, France
    Med Mal Infect 37:354-6. 2007
    ..Furthermore, severe infections caused by this pathogen can occur in immunocompetent patients, so that the implication of specific host factors in the severity of the disease can be suspected. Genetic features could be one of these...
  45. doi request reprint Impact of viral eradication on mortality related to hepatitis C: a modeling approach in France
    Sylvie Deuffic-Burban
    CTRS INSERM U795, CHRU Lille, Lille, France
    J Hepatol 49:175-83. 2008
    ..In France, two recent studies enabled modeling of the impact of viral eradication on HCV mortality...
  46. ncbi request reprint Incidence rate and risk factors for loss to follow-up in HIV-infected patients from five French clinical centres in Northern France - January 1997 to December 2006
    Bakhao Ndiaye
    CIRE Nord, Lille, France
    Antivir Ther 14:567-75. 2009
    ..Our goal was to determine the incidence rate and risk factors for loss to follow-up (LTFU) of HIV-infected patients in Northern France...
  47. doi request reprint Characteristics of and outcomes in HIV-infected patients who return to care after loss to follow-up
    Bakhao Ndiaye
    CIRE Nord, Lille, Cedex, France
    AIDS 23:1786-9. 2009
    ..Upon returning to care, 33 out of 74 patients (44.6%) had CD4 cell counts less than 200/mm and/or AIDS. Patients who returned to care after LTFU were five times more likely to die than patients who attended clinic regularly...
  48. ncbi request reprint Hyperlactataemia during antiretroviral therapy: incidences, clinical data and treatment
    Yann Gerard
    Service Regional Universitaire des Maladies Infectieuses et du Voyageur, Hôpital Dron, Tourcoing, France
    Therapie 58:153-8. 2003
    ..The early diagnosis of cases was the result of great vigilance and, combined with routine measurements of the anion gap, might be the most crucial factor explaining the low mortality rate observed here...
  49. ncbi request reprint Factors determining length of the postoperative hospital stay after major head and neck cancer surgery
    Nicolas Penel
    Département de Cancérologie Générale, Centre Oscar Lambret, 3 Rue F Combemale, Lille, France
    Oral Oncol 44:555-62. 2008
    ..Two variables (duration of surgical procedure and occurrence of nosocomial infections) were associated with LOS and might be improved by appropriate strategies...
  50. doi request reprint Needle puncture and transcutaneous bone biopsy cultures are inconsistent in patients with diabetes and suspected osteomyelitis of the foot
    Eric Senneville
    Diabetic Foot Clinic, Gustave Dron Hospital, Tourcoing, France
    Clin Infect Dis 48:888-93. 2009
    ..However, no studies have compared needle puncture with concomitant transcutaneous bone biopsy, which is the current standard recommended in international guidelines...
  51. doi request reprint Outcome of diabetic foot osteomyelitis treated nonsurgically: a retrospective cohort study
    Eric Senneville
    Diabetic Foot Clinic, Dron Hospital, Tourcoing, France
    Diabetes Care 31:637-42. 2008
    ..The purpose of this article was to identify criteria predictive of remission in nonsurgical treatment of diabetic foot osteomyelitis...
  52. ncbi request reprint Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients
    Alfredo Alberti
    J Hepatol 42:615-24. 2005
  53. ncbi request reprint Impact of human immunodeficiency virus type 1 subtype on first-line antiretroviral therapy effectiveness
    Laurence Bocket
    Virology Department, Centre Hospitalier Universitaire de Lille, France
    Antivir Ther 10:247-54. 2005
    ..The effectiveness of antiretroviral treatment (ART) was compared in 416 naive patients from a French clinical cohort infected with B and non-B HIV-1 subtypes...
  54. ncbi request reprint Clinical and immunological effects of a 6 week immunotherapy cycle with murabutide in HIV-1 patients with unsuccessful long-term antiretroviral treatment
    George M Bahr
    Laboratory of Molecular Immunology of Infection and Inflammation, Pasteur Institute of Lille, 1 rue du Professeur Calmette, BP 245, 59019 Lille Cedex, France
    J Antimicrob Chemother 51:1377-88. 2003
    ..These results warrant further evaluation of extended periods or cycles of murabutide immunotherapy as adjunct to HAART...
  55. ncbi request reprint Review of human immunodeficiency virus type 1-related opportunistic infections in sub-Saharan Africa
    Charles B Holmes
    Division of Infectious Disease, Partners AIDS Research Center, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
    Clin Infect Dis 36:652-62. 2003
    ..Policies regarding the type and timing of opportunistic infection prophylaxis may be region specific and urgently require further study...
  56. ncbi request reprint Severe liver toxicity in postexposure prophylaxis for HIV infection with a zidovudine, lamivudine and fosamprenavir/ritonavir regimen
    Simona Pavel
    AIDS 21:268-9. 2007
  57. ncbi request reprint [When to initiate antiretroviral therapy and what to start with?]
    Nathalie Viget
    Service régional universitaire des maladies infectieuses, Centre Hospitalier de Tourcoing, 59208, Tourcoing Cedex
    Rev Prat 56:953-63. 2006
    ....
  58. ncbi request reprint Characteristics trends, mortality and morbidity in persons newly diagnosed HIV positive during the last decade: the profile of new HIV diagnosed people
    C Delpierre
    INSERM U558, IFR126, Toulouse, F 31073, France
    Eur J Public Health 18:345-7. 2008
    ..This population is mainly diagnosed late with major consequences on morbidity and mortality...
  59. pmc Scaling up antiretroviral therapy in South Africa: the impact of speed on survival
    Rochelle P Walensky
    The Divisions of Infectious Disease, Department of Medicine, Massachusetts General Hospital, Boston, MA 02114, USA
    J Infect Dis 197:1324-32. 2008
    ..Only 33% of eligible human immunodeficiency virus (HIV)-infected patients in South Africa receive antiretroviral therapy (ART). We sought to estimate the impact of alternative ART scale-up scenarios on patient outcomes from 2007-2012...
  60. ncbi request reprint Analysis of costs attributable to an outbreak of severe acute respiratory syndrome at a French hospital
    Yazdan Yazdanpanah
    Infect Control Hosp Epidemiol 27:1282-5. 2006
  61. pmc HIV drug resistance surveillance for prioritizing treatment in resource-limited settings
    Rochelle P Walensky
    Division of Infectious Disease, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    AIDS 21:973-82. 2007
    ..Sentinel testing programs for HIV drug resistance in resource-limited settings can inform policy on antiretroviral therapy (ART) and drug sequencing...
  62. pmc The independent effect of highly active antiretroviral therapy on severe opportunistic disease incidence and mortality in HIV-infected adults in Côte d'Ivoire
    Elena Losina
    Department of Biostatistics and Epidemiology, Boston University School of Public Health, Boston, MA, USA
    Antivir Ther 12:543-51. 2007
    ..Studies in developed countries have shown highly active antiretroviral therapy (HAART) decreases incidence of severe opportunistic diseases (ODs) in HIV-infected patients beyond that which is expected from changes in CD4+ T-cell count...
  63. doi request reprint Natural polymorphisms in HIV-1 protease: impact on effectiveness of a first-line lopinavir-containing antiretroviral therapy regimen
    Karen Champenois
    Tourcoing AIDS reference centre, France
    J Med Virol 80:1871-9. 2008
    ..However, polymorphisms may affect ART effectiveness differently in other populations, such as ART-experienced patients and/or patients treated with protease inhibitors other than the one used here...
  64. ncbi request reprint Cost-effectiveness of HIV treatment in resource-poor settings--the case of Côte d'Ivoire
    Sue J Goldie
    Department of Health Policy and Management, Program in Health Decision Science, Harvard School of Public Health, Boston, MA 02115, USA
    N Engl J Med 355:1141-53. 2006
    ..As antiretroviral therapy is increasingly used in settings with limited resources, key questions about the timing of treatment and use of diagnostic tests to guide clinical decisions must be addressed...
  65. pmc Baseline CD4 cell count and outcome of pegylated interferon plus ribavirin therapy in HIV/hepatitis C virus-coinfected patients
    Laure Valerio
    Departement de sante publique, Centre Hospitalier Universitaire de Nice, Nice, France
    J Acquir Immune Defic Syndr 47:50-5. 2008
    ..Our objective was to determine if a baseline CD4 count >/=350 cells/mm predicts a sustained HCV response to pegylated interferon plus ribavirin...
  66. ncbi request reprint Kaposi's sarcoma in HIV-infected patients: when and how should we evaluate bone involvement?
    Sophie Nguyen
    AIDS 21:2251-2. 2007
  67. ncbi request reprint WHO Rapid Advice Guidelines for pharmacological management of sporadic human infection with avian influenza A (H5N1) virus
    Holger J Schunemann
    Italian National Cancer Institute Regina Elena, INFORMA Unit, Department of Epidemiology, Istituto Regina Elena, Rome, Italy
    Lancet Infect Dis 7:21-31. 2007
    ..Emergence of other novel influenza A viral subtypes with pandemic potential, or changes in the pathogenicity of H5N1 virus strains, will require an update of these guidelines and WHO will be monitoring this closely...
  68. pmc Introduction of SARS in France, March-April, 2003
    Jean Claude Desenclos
    Département Maladies Infectieuses, Institut de Veille Sanitaire, Saint Maurice, France
    Emerg Infect Dis 10:195-200. 2004
    ..Timely detection, isolation of probable case-patients, and quarantine of their contacts appear to have been effective in preventing the secondary spread of SARS in France...
  69. ncbi request reprint Risk factors for anaemia in patients on prolonged linezolid therapy for chronic osteomyelitis: a case-control study
    Eric Senneville
    Infectious Diseases Department, Dron Hospital, 135 rue du Président Coty, 59200 Tourcoing, France
    J Antimicrob Chemother 54:798-802. 2004
    ..The intrinsic properties of the new antibiotic linezolid make it an attractive candidate for the treatment of chronic osteomyelitis. However, data regarding the tolerance of long-term linezolid administration are still lacking...
  70. doi request reprint Risk factors for grade 3 or 4 gamma-glutamyl transferase elevation in HIV/hepatitis C virus-coinfected patients
    Firouzé Bani-Sadr
    AIDS 22:1234-6. 2008
  71. ncbi request reprint Effectiveness and tolerability of prolonged linezolid treatment for chronic osteomyelitis: a retrospective study
    Eric Senneville
    Infectious Diseases Department, Dron Hospital of Tourcoing, 135 rue du Président Coty, 59200 Tourcoing, France
    Clin Ther 28:1155-63. 2006
    ..Linezolid is an oxazolidinone agent which is apparently well designed for treating chronic osteomyelitis, but data on effectiveness and tolerability as prolonged therapy is currently lacking...
  72. ncbi request reprint Risk factors for early catheter-related infections in cancer patients
    Nicolas Penel
    Department of General Oncology, Oscar Lambret Cancer Center, Lille, France
    Cancer 110:1586-92. 2007
    ..The authors conducted a prospective study to identify the risk factors for developing early catheter-related infection...